Glenmark Pharmaceuticals has informed that a meeting of the Board of Directors of the Company will be held on October 30, 2014, to consider and approve the Company’s Unaudited Financial Statements for the Second Quarter/Half year ended September 30, 2014 (Q2). Further, as per the ‘Code of Conduct for Prevention of Insider Trading' of the Company, the trading window shall remain closed for Directors and other designated employees of the Company from October 17, 2014 to October 31, 2014 for the purpose of approval of Unaudited Financial Results for the Second Quarter/Half year ended September 30, 2014.
The above information is a part of company’s filings submitted to BSE.
